Greystone Associates Assesses the Potential and Prospects for Pipeline Candidates Targeting Multiple Sclerosis and their Probable Impact on Existing
Treatments

A study from a team of researchers led by Dr. Andrew P. Makrigiannis, Director of the Molecular Immunology Research Unit at the IRCM, has identified a new mechanism regulating interferon production.

Greystone Associates Report Analyzes Clinical, Regulatory and Therapeutic Factors Driving Growth of Powerful New Drugs Based on the Human Immune Response

A new study on predicting outcomes of standard treatment for hepatitis C virus (HCV) infection found that a number of factors impacted responses, including the form of the interferon given. However, for some genotypes of the disease, few of these factors play a role.